Awareness and Collaboration Across Stakeholder Groups Important for eConsent Achieving Value-Driven Adoption (English)
Free access
- New search for: Vanaken, Hilde
- New search for: Masand, Shirley N.
- Further information on Masand, Shirley N.:
- https://orcid.org/0000-0002-7345-1764
- New search for: Vanaken, Hilde
- New search for: Masand, Shirley N.
- Further information on Masand, Shirley N.:
- https://orcid.org/0000-0002-7345-1764
In:
Therapeutic Innovation & Regulatory Science
;
53
, 6
; 724-735
;
2019
-
ISSN:
- Article (Journal) / Electronic Resource
-
Title:Awareness and Collaboration Across Stakeholder Groups Important for eConsent Achieving Value-Driven Adoption
-
Contributors:Vanaken, Hilde ( author ) / Masand, Shirley N. ( author )
-
Published in:Therapeutic Innovation & Regulatory Science ; 53, 6 ; 724-735
-
Publisher:
- New search for: Springer International Publishing
- New search for: Springer Nature
-
Place of publication:[New York]
-
Publication date:2019
-
ISSN:
-
ZDBID:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
- New search for: 44.38 / 44.38
- Further information on Basic classification
-
Keywords:
-
Classification:
-
Source:
Table of contents – Volume 53, Issue 6
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 721
-
The Problem With Current Proposals to Address High Medicare Part B Drug PricesDaniel, Gregory W. et al. | 2019
- 724
-
Awareness and Collaboration Across Stakeholder Groups Important for eConsent Achieving Value-Driven AdoptionVanaken, Hilde / Masand, Shirley N. et al. | 2019
- 736
-
Industry Assessment of the Contribution of Patient Support Programs, Market Research Programs, and Social Media to Patient SafetyJokinen, Jeremy / Bertin, Dominique / Donzanti, Bruce / Hormbrey, Janet / Simmons, Valerie / Li, Hal / Dharmani, Charles / Kracht, Karolyn / Hilzinger, Thomas S. / Verdru, Peter et al. | 2019
- 746
-
Tying Medicare Part B Drug Prices to International Reference Pricing Will Devastate R&DSchulthess, Duane / Gassull, Daniel / Maisel, Steven et al. | 2019
- 752
-
Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016Alexander, G. Caleb / Ogasawara, Ken / Wiegand, Dana / Lin, Dora / Breder, Christopher D. et al. | 2019
- 759
-
Potential Use of Artificial Intelligence for Regulatory Intelligence: Biopharmaceutical Industry’s ViewsMayer, Mark / Canedo, Angelica / Dinh, Tam / Low, Madelyn / Ortiz, Ariel / Garay, Chloé et al. | 2019
- 767
-
The Meanings of “Pediatric Drug Development”Rose, Klaus / Grant-Kels, Jane M. et al. | 2019
- 775
-
Recalls and Premarket Review Systems for High-Risk Medical Devices in JapanNakayama, Motoko / Tanaka, Shiro / Hamada, Shota / Uchida, Takahiro / Kawakami, Koji et al. | 2019
- 781
-
Pharmacovigilance in India in Comparison With the USA and European Union: Challenges and PerspectivesJose, Jobin / Rafeek, Naziya Refi et al. | 2019
- 787
-
Scope of Improvement in the Functioning of National Regulatory Authority—A Step Toward International Accreditation: A Qualitative Study From PakistanIkram, Raazeyah / Saqib, Anum / Mushtaq, Irem / Atif, Muhammad et al. | 2019
- 795
-
Detecting Adverse Drug Events: Accuracy and GeneralizabilityWalter, Scott R. / Gallego, Blanca et al. | 2019
- 797
-
Erratum to “Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development”Yen, Elizabeth / Davis, Jonathan M. / Milne, Christopher-Paul et al. | 2019